# A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

> **NCT06698796** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 211 (estimated)

## Conditions studied

- Dermatomyositis
- Polymyositis

## Interventions

- **DRUG:** Dazukibart

## Key facts

- **NCT ID:** NCT06698796
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-11-25
- **Final completion:** 2027-11-25
- **Target enrollment:** 211 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698796, "A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06698796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*